Cellectar Biosciences INC NEW (CLRB)

Price$2.97

Value ScoreF

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-4.58%

Price vs S&P 500 (4W)11.76%

VGM Score24.77

Market Capitalization$24.85M

All Metrics

Book Value / Share (Quarterly)$1.11

P/TBV (Annual)1.66x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-4.38

Price vs S&P 500 (YTD)-4.49%

Net Profit Margin (TTM)-24744.44%

EPS (TTM)$-7.41

10-Day Avg Trading Volume0.24M

EPS Excl Extra (TTM)$-7.41

EPS (Annual)$-8.35

ROI (Annual)-219.69%

Cash / Share (Quarterly)$1.97

ROA (Last FY)-145.48%

EBITD / Share (TTM)$-6.77

ROE (5Y Avg)-157.80%

Operating Margin (TTM)-11300.00%

Cash Flow / Share (Annual)$-5.45

P/B Ratio5.27x

P/B Ratio (Quarterly)2.28x

Net Income / Employee (Annual)$-1,981,000

EV / Revenue (TTM)183.42x

Net Interest Coverage (TTM)-10.07x

ROA (TTM)-153.18%

EPS Incl Extra (Annual)$-8.35

Current Ratio (Annual)2.96x

Quick Ratio (Quarterly)1.71x

3-Month Avg Trading Volume0.71M

52-Week Price Return-59.74%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.46

P/S Ratio (Annual)248.55x

Asset Turnover (Annual)0.01x

52-Week High$20.70

EPS Excl Extra (Annual)$-8.35

CapEx CAGR (5Y)-37.16%

Tangible BV CAGR (5Y)11.30%

26-Week Price Return11.35%

Quick Ratio (Annual)2.78x

13-Week Price Return-10.54%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.90x

Enterprise Value$16.51M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-24.66%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-22270.00%

Cash / Share (Annual)$3.11

3-Month Return Std Dev73.75%

Net Income / Employee (TTM)$-1,894,600

ROE (Last FY)-219.69%

Net Interest Coverage (Annual)-13.03x

EPS Basic Excl Extra (Annual)$-8.35

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-7.41

ROI (TTM)-264.79%

P/S Ratio (TTM)276.16x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.65

Price vs S&P 500 (52W)-87.95%

Year-to-Date Return6.44%

5-Day Price Return-1.88%

EPS Normalized (Annual)$-8.35

ROA (5Y Avg)-174.40%

Net Profit Margin (Annual)-22270.00%

Month-to-Date Return20.77%

Cash Flow / Share (TTM)$-3.44

EBITD / Share (Annual)$-8.73

Operating Margin (Annual)-10170.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-157.80%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-7.41

P/TBV (Quarterly)5.65x

P/B Ratio (Annual)1.26x

Pretax Margin (TTM)-24744.44%

Book Value / Share (Annual)$2.34

Price vs S&P 500 (13W)-20.29%

Beta0.53x

Revenue / Share (TTM)$0.00

ROE (TTM)-264.79%

52-Week Low$2.43

vGradeF

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-1.30est. -1.92

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

4.11

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CLRBCellectar Biosciences INC NEW	F	—	D	$2.97
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Cellectar Biosciences is a clinical-stage biopharmaceutical company developing cancer therapeutics using its proprietary phospholipid drug conjugate (PDC) delivery platform. The company's PDC technology is designed to selectively target cancer cells, potentially offering improved efficacy with reduced off-target toxicity compared to conventional approaches. Cellectar is leveraging this platform to build a pipeline of oncology drugs aimed at addressing unmet patient needs in cancer treatment.